Selexipag - Generic Drug Details

What are the generic drug sources for selexipag and what is the scope of freedom to operate?

Selexipag is the generic ingredient in two branded drugs marketed by Actelion, Alembic, and Zydus Lifesciences, and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selexipag has one hundred and seventy-seven patent family members in forty-two countries.

There are two drug master file entries for selexipag. Three suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for selexipag

International Patents:	177
US Patents:	6
Tradenames:	2
Applicants:	3
NDAs:	4
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	24
Patent Applications:	996
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for selexipag
What excipients (inactive ingredients) are in selexipag?	selexipag excipients list
DailyMed Link:	selexipag at DailyMed

Recent Clinical Trials for selexipag

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1
Sheffield Teaching Hospitals NHS Foundation Trust	Phase 4
University of Glasgow	Phase 4

See all selexipag clinical trials

Generic filers with tentative approvals for SELEXIPAG

Applicant	Application No.	Strength	Dosage Form
		600MCG	TABLET;ORAL
		400MCG	TABLET;ORAL
		200MCG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for selexipag

Drug Class	Prostacyclin Receptor Agonist
Mechanism of Action	Prostacyclin Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for selexipag

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for SELEXIPAG

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
UPTRAVI	For Injection	selexipag	1.8 mg/vial	214275	1	2022-07-29
UPTRAVI	Tablets	selexipag	0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg and 1.6 mg	207947	4	2019-12-23

US Patents and Regulatory Information for selexipag

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-008	Dec 21, 2015	AB	RX	Yes	No	9,284,280*PED				Y
Alembic	SELEXIPAG	selexipag	TABLET;ORAL	214414-003	Oct 11, 2023	AB	RX	No	No
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-005	Dec 21, 2015		RX	Yes	No	10,821,108*PED				Y

EU/EMA Drug Approvals for selexipag

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen Cilag International NV	Uptravi	selexipag	EMEA/H/C/003774Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.,	Authorised	no	no	no	2016-05-12

International Patents for selexipag

Country	Patent Number	Title	Estimated Expiration
Croatia	P20180171
South Korea	20170024165
Cyprus	1122641

Supplementary Protection Certificates for selexipag

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1400518	44/2016	Austria		PRODUCT NAME: SELEXIPAG ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083 (MITTEILUNG) 20160519
2447254	325 10-2018	Slovakia		PRODUCT NAME: SELEXIPAG; REGISTRATION NO/DATE: EU/1/15/1083 20160519
2447254	2018015	Norway		PRODUCT NAME: 2-4-(N-(5,6-DIFENYLPYRAZIN-2- YL)-N- ISOPROPYLAMINO)BUTYLOKSY-N-; REG. NO/DATE: EU/1/15/1083 20160530

Selexipag: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Selexipag, a selective prostacyclin receptor (IP receptor) agonist, generated $1.3 billion in net sales in 2022. The drug is indicated for the treatment of pulmonary arterial hypertension (PAH). Its market performance is influenced by patent exclusivity, clinical trial outcomes, and competitive landscape.

What is Selexipag's Current Market Position?

Selexipag, marketed as Uptravi, operates within the rare disease pharmaceutical sector, specifically targeting PAH. This condition affects an estimated 15 to 50 individuals per million globally. The drug's efficacy in improving exercise capacity and reducing the risk of clinical worsening events positions it as a significant therapeutic option.

Sales Performance Analysis

Selexipag's net sales have shown consistent growth since its approval.

• 2020: $906 million
• 2021: $1.16 billion
• 2022: $1.30 billion [1]

This trajectory indicates increasing market penetration and physician adoption. The drug's expansion into various geographic markets and indications contributes to this growth.

Geographic Distribution of Sales

Sales are distributed across major pharmaceutical markets:

• North America: Represents the largest share of selexipag revenue.
• Europe: A substantial contributor, with increasing adoption rates.
• Asia-Pacific: Demonstrates significant growth potential, driven by expanding healthcare access and diagnosis rates.
• Rest of the World: Contributes a smaller but growing portion of global sales.

Patient Population and Treatment Landscape

PAH is a progressive disease requiring long-term management. Selexipag offers an oral administration route, a key differentiating factor from intravenous or inhaled prostacyclin therapies, potentially improving patient adherence and quality of life. The treatment landscape for PAH includes other drug classes such as endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors (PDE5is). Selexipag's mechanism of action provides a distinct therapeutic pathway.

What is Selexipag's Patent and Exclusivity Status?

Patent protection is critical to selexipag's financial performance, safeguarding its market exclusivity against generic competition.

Key Patents and Expiration Dates

Selexipag's patent portfolio includes multiple patents covering its composition of matter, manufacturing processes, and methods of use. A key composition of matter patent in the United States (U.S. Patent No. 8,354,442) is scheduled to expire in 2023. However, the drug's market exclusivity is also protected by other mechanisms.

• U.S. Patent Expiration (Composition of Matter): 2023
• Other U.S. Patents (Process/Method of Use): Varying expiration dates, extending beyond 2023.
• European Patent Expiration: Varies by country, with some extensions available under supplementary protection certificates (SPCs).

The existence of multiple patents and potential for patent term extensions or litigation can influence the actual timing of generic entry.

Regulatory Exclusivity

In addition to patent protection, selexipag benefits from regulatory exclusivity periods granted by regulatory authorities.

• U.S. New Chemical Entity (NCE) Exclusivity: 5 years from approval (September 30, 2015). This period expired in 2020.
• Orphan Drug Exclusivity (ODE): 7 years in the U.S. for orphan-designated drugs, which applies to selexipag due to its indication for PAH. This exclusivity is expected to provide protection until at least 2025.
• European Market Exclusivity: 10 years from marketing authorization in the EU, with a potential for a 2-year extension to 12 years for specific indications or market penetration, and an additional 1 year for new indications.

The interplay between patent expiries and regulatory exclusivity dictates the duration of market exclusivity and the subsequent competitive landscape.

What are the Competitive Threats to Selexipag?

The PAH market is characterized by ongoing innovation and the presence of multiple therapeutic agents.

Existing Competitors

Selexipag competes with established drug classes and specific branded products:

• Endothelin Receptor Antagonists (ERAs): Bosentan (Tracleer), Ambrisentan (Letairis/Volibris), Macitentan (Opsumit). Macitentan is a direct competitor to selexipag in terms of its oral administration and efficacy profile.
• Phosphodiesterase-5 Inhibitors (PDE5is): Sildenafil (Revatio/Pulmozyme), Tadalafil (Adcirca).
• Soluble Guanylate Cyclase (sGC) Stimulators: Riociguat (Adempas).
• Prostacyclin Analogs: Iloprost (Ventavis - inhaled), Treprostinil (Remodulin - subcutaneous/intravenous; Tyvaso - inhaled).

The presence of these therapies creates a complex treatment algorithm where patient characteristics, disease severity, and prior treatment history influence drug selection.

Pipeline Threats and Emerging Therapies

The PAH drug pipeline includes novel mechanisms of action and reformulations of existing therapies. These emerging treatments could pose future competitive challenges.

• Novel Mechanisms: Research is ongoing into therapies targeting inflammatory pathways, fibrosis, and cellular proliferation.
• Combination Therapies: Development of fixed-dose combinations or synergistic drug regimens could alter the competitive landscape by offering enhanced efficacy or improved convenience.
• Biologics: While currently less prevalent in PAH, biologic therapies are being explored for other pulmonary vascular diseases.

The pace of clinical development and regulatory approval for these pipeline candidates will determine their impact on selexipag's market share.

What is Selexipag's Financial Outlook?

Selexipag's financial trajectory is projected to be influenced by patent expiries, market expansion, and ongoing competition.

Projected Revenue Growth

Analysts project continued revenue growth for selexipag in the short to medium term, driven by its established efficacy and growing awareness of PAH. However, revenue is expected to decline post-patent expiry and the entry of generics.

• 2023 Projection: Expected to exceed 2022 figures, benefiting from continued market exclusivity.
• Post-Patent Expiry (from 2024/2025 onwards): Gradual erosion of market share due to generic competition is anticipated. The rate of erosion will depend on the pricing strategies of generic manufacturers and the ability of selexipag's innovator to maintain market share through brand loyalty, physician preference, and potential lifecycle management strategies.

Impact of Generic Entry

The expiration of key patents will pave the way for generic versions of selexipag.

• Generic Pricing: Generic competitors typically enter the market at significantly lower price points, leading to a substantial reduction in the price of the drug.
• Market Share Shift: Generic entry often results in a rapid transfer of market share from the innovator product to generic alternatives, especially in markets with price-sensitive healthcare systems.
• Innovator Strategy: The innovator company's strategy to mitigate the impact of generic entry may include developing new formulations, pursuing new indications, or focusing on specific patient segments.

Investor Considerations

For investors, selexipag represents a mature product with a finite period of peak sales.

• Current Investment Thesis: Investment in selexipag's innovator company is based on its current strong sales performance and market position.
• Future Risk Assessment: Future investment decisions will need to account for the impending patent expiries and the potential revenue decline post-generic entry. The company's pipeline and diversification strategies will be crucial factors in assessing long-term value.

Key Takeaways

• Selexipag generated $1.3 billion in net sales in 2022 and exhibits consistent revenue growth driven by its efficacy in treating PAH.
• The drug benefits from a combination of patent protection and regulatory exclusivity, with key patents expiring around 2023 and orphan drug exclusivity extending to approximately 2025.
• Competitive threats include established PAH therapies such as ERAs, PDE5is, and sGC stimulators, as well as emerging pipeline candidates.
• The financial outlook for selexipag anticipates continued growth in the short term, followed by a projected decline in revenue post-generic entry.

Frequently Asked Questions

1. When did selexipag receive its initial U.S. regulatory approval? Selexipag received its initial U.S. regulatory approval on September 30, 2015.
2. What is the primary mechanism of action for selexipag? Selexipag is a selective prostacyclin receptor (IP receptor) agonist.
3. What are the main therapeutic areas selexipag is approved for? Selexipag is approved for the treatment of pulmonary arterial hypertension (PAH).
4. What are the key patent expiration dates that could impact selexipag's market exclusivity? A key composition of matter patent in the United States is scheduled to expire in 2023.
5. Which classes of drugs are considered direct competitors to selexipag in the PAH market? Endothelin receptor antagonists (ERAs), particularly macitentan, and phosphodiesterase-5 inhibitors (PDE5is) are considered direct competitors.

Citations

[1] Actelion Pharmaceuticals Ltd. (2023). 2022 Annual Report. Retrieved from https://www.actelion.com/ (Note: Specific report location may vary, access via company investor relations).